CLAIMS

1. Use of a composition comprising IGFBP7 in the manufacture of a medicament for the adjunct treatment of severe or cerebral malaria.

2. The use according to claim 1, wherein the medicament inhibits IRBC-endothelial cytoadherence.

3. The use according to any one of claims 1 or 2, wherein the composition further comprises a Von Willebrand Factor (VWF) and/or a thrombospondin-1 (TSP-1).

4. The use according to claim 3, wherein the amount of VWF present in the composition is ~~about~~ between 0.125 and 0.5 IU/ml.

5. The use according to claim 3, wherein the amount of the TSP-1 present in the composition is ~~about~~ at least 10 ng/ml.

6. The use according to any one of the preceding claims, wherein the amount of IGFBP7 present in the composition is about at least 100 ng/ml.

7. The use according to any one of the preceding claims, wherein the IGFBP7 is used as ~~an adjunction treatment~~ together with one or more other anti-malarial drugs.

8. The use according to claim 7, wherein the anti-malarial drugs are selected from the group comprising artemisinin or artesunate and its derivatives, chloroquine, mefloquine pyrimethamine, sulfadoxine, amodiaquine, quinine/quinidine, halofantrine,~~,~~ atovaquone, proguanil and doxycycline.

~~9. A composition comprising IGFBP7 for use as an adjunct treatment in an individual afflicted with malaria.~~

~~10. The composition according to claim 9, wherein the composition further comprises a Von Willebrand Factor (VWF) and/or a thrombospondin-1 (TSP-1).~~

~~11. The composition according to claim 10, wherein the amount of VWF present in the composition is about between 0.125 and 0.5 IU/ml.~~

~~12. The composition according to claim 10, wherein the amount of the TSP-1 present in the composition is about 10 ng/ml.~~

~~13. The composition according to any one of claims 9 to 12, wherein the amount of IGFBP7 present in the composition is about at least 100 ng/ml.~~

~~14. The composition according to any one of claims 9 to 13, wherein the IGFBP7 is in an admixture with one or more other anti-malarial drugs.~~

~~15. The composition according to claim 14, wherein the anti-malarial drugs are selected from the group comprising artemisinin or artesunate and its derivatives, chloroquine, mefloquine pyrimethamine, sulfadoxine, amodiaquine, quinine/quinidine, halofantrine, , tovaquone, proguanil and doxycycline.~~

~~16. A method of treating an individual afflicted with malaria comprising administering to the individual in need of such treatment an effective amount of a medicament containing IGFBP7.~~

~~17. The method according to claim 16, wherein the medicament further comprises a Von Willebrand Factor (VWF) and/or a thrombospondin-1 (TSP-1).~~

~~18. The method according to claim 17, wherein the amount of VWF administered to the individual is about between 0.125 and 0.5 IU/ml.~~

~~19. The method according to claim 17, wherein the amount of the TSP-1 administered to the individual is about 10 ng/ml.~~

~~20. The method according to any one of claims 16 to 19, wherein the amount of IGFBP7 administered to the individual is about at least 100 ng/ml.~~